乌龙制药 URGN 深 沪
等待开盘 07-30 09:30:00 美东时间
18.90
0.000
0.00%
华盛通- 最 高19.0455
- 今 开18.90
- 成交量 90.95万股
- 最 低 18.37
- 昨 收 18.90
- 总市值 8.71亿
- 52周最高 19.355
- 市盈率 静 --
- 换手率 1.97%
- 52周最低 3.42
- 委 比 -91.88%
- 总股本 4610.75万
- 历史最高 69.568
- 量 比 0.55
- 振 幅 3.57%
- 历史最低 3.42
- 每 手 1
- 风险率 1.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
UroGen Pharma Ltd. will report its second quarter 2025 financial results on August 7, 2025, followed by a live webcast and conference call at 10:00 AM ET. The webcast will be available on UroGen’s Investor Relations website, with a replay accessible for 30 days. UroGen specializes in developing innovative treatments for urothelial and specialty cancers using its RTGel reverse-thermal hydrogel technology.
07-29 12:00
UroGen Pharma Announces Publication In Reviews In Urology Of Results From Phase 3b Study Evaluating Feasibility Of Administering ZUSDURI For Intravesical Solution In Home Setting
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, today announced the publication in Reviews in Urology of results
07-28 20:08
UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma announced the publication of results from a five-year long-term extension study of the Phase 2b OPTIMA II trial evaluating ZUSDURI (mitomycin) for intravesical solution in patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The study demonstrated durable, long-term complete responses (CRs) in patients who achieved initial CR with ZUSDURI. Among 17 patients entering long-term follow-up, the med...
07-21 12:00
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. announced the completion of patient enrollment in its Phase 3 UTOPIA clinical trial for UGN-103, a next-generation formulation of mitomycin for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The trial enrolled 99 patients globally and utilizes UroGen’s RTGel technology, offering potential improvements over ZUSDURI, including simplified manufacturing and reconstitution pr...
07-07 12:00
UroGen Pharma Approves Bonuses After FDA Approval
Urogen Pharma ( ($URGN) ) has shared an update. On June 30, 2025, UroGen Pharma...
07-04 04:50
EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria
Telomir-1 improved cell survival, reduced oxidative stress, and restored mitochondrial balance in preclinical progeria study.
06-18 21:00
【爱建医药】ADA 2025蓄势待发，关注减肥药赛道
（转自：爱建证券研究所） ADA 2025 蓄势待发，关注 减肥药赛道 -爱建生物医药行业周报- 本报告发布于2025年06月17日 投资要...
06-18 10:28
美股机会日报丨段永平“晒单”卖出苹果看跌期权！Circle盘前再涨8%！零售巨头探索发行稳定币
段永平捞底苹果！“晒单”卖出144万美元看跌期权；Circle盘前再涨8%！沃尔玛、亚马逊探索发行稳定币；高盛唱多中国“十巨头”股票>>
06-16 20:00
美股大行评级 | 潜在涨幅290.69%！乌龙制药获丰业银行升目标价至47美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140565699993591809.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 丰业银行：维持乌龙制药(URGN)"跑赢大市"评级，目标价从23美元升至47美元</p> <p>• Guggenheim：维持ADC Therapeutics(ADCT)"买入"评级，目标价从7美元升至10美元</p>
06-16 08:40
Why BP Stock Is Trading Higher During Friday's Session
Energy stocks, with BP among the leaders, are trading higher Friday. Crude oil prices head for their strongest weekly rally since October 2022.
06-14 03:57
